valu usd unless otherwis note
guidanc still appear conserv
view mdt quarterli result achiev level consist
past three quarter growth rate approach
compani faster grow peer despit ytd ralli vs
 believ room multipl expans
share price appreci envis beat-and-rais rest
base manag conserv guidanc
increas y/i cc guidanc revenu
growth four busi segment well mdt forecast
perform parallel result aptli reflect trend
key growth driver diabet csh brain pain therapi
atrial fibril pace advanc energi advanc stapl
strength busi off-set isol pocket
weak portfolio spine defibril system specialti
therapi non-gaap ep rbce lower tax rate
bigger fx contribut account upsid
diabet group deliv big beat versu estim dg revenu
jump y/i twice estim impress perform
despit easi comp revenu growth neg
attribut strong uptak minim
intern number train activ user increas
almost past quarter manag note
percentag point increas market share pump launch
guardian connect cgm underway despit competit
two incumb believ cgm market
grow fast enough support multipl competitor
believ revis guidanc cc revenu growth still
conserv cc revenu growth exceed high end
guidanc bp increas cc revenu growth
guidanc bp thu chang
guidanc basic reflect upsid assum cc revenu
growth easier comp cc growth
low bar despit difficult comp opinion believ
revenu non-gaap ep guidanc remain
increas cc ep off-set compar
decreas fx contribut neutral ep
increas estim cc revenu growth ep price target goe
new revenu ep estim
old revenu estim base
cc growth bp increas previou estim stronger
fx headwind vs previous bring revenu
estim price target base
ep still discount faster grow peer
price prior trade day market close estimate unless otherwis note
forecast least organ growth
cvg rtg mitg expect grow around
diabet group higher rate believ around
guidanc impli ww revenu close
requir addit year
estim therapi innov contribut approxim
half revenu growth balanc come
global expans especi emerg market value-
tavr micra reveal linq remain key growth
driver cvg high-growth market within cvg
tavr diagnost mid-teen follow endoven
atrial fibril lvad high single-digit low double-
digit plan introduc largest valv
size evolut mm potenti low-risk
indic enhanc micra convert
dual-chamb devic significantli expand potenti
market next-gener icm reveal linq ii also
schedul launch
double-digit growth emerg market expect
continu em revenu increas
compris ww revenu forti percent em
revenu came greater china middl east
 africa latin america switch
indirect direct distribut major impact
em growth margin also made infrastructur
invest key market enabl market access
oper margin target appear realist lower
goal annual improv bp
bp increas everi year june investor day
enterpris excel program lie heart achiev
target accordingli ep growth target also
come cc includ modest
currenc volatil reason move away cc
ep guidanc fx exposur fulli hedg
sever currenc especi emerg market
becom bigger compon revenu
bloomberg capit market estim upside/downside/target
price target base price-to-earnings multipl
ep y/i mdt current price-to-earnings multipl
ep estim around key assumpt
underli ep estim revenu growth
basi point oper margin
expans fiscal year excess free cash
flow dividend deploy primarili share
buy-back target price-to-earnings price-to-earnings ntm
averag share
upsid scenario base price-to-earnings multipl
cy ep key assumpt underli
ep estim revenu growth
achiev combin accret
superior perform key product categori tavr
leadless pace neurovascular neurosurgeri diabet
surgic innov basi point oper
margin expans
downsid scenario base price-to-earnings multipl
cy ep key assumpt underli ep
estim revenu growth
basi point oper margin expans
meaning share buy-back
exhibit revenu contribut segment geographi
exhibit revenu guidanc
compani report capit market figur million
geographi geographi internationalgeographi worldwiderevenu revenu growth y/ycontribut revenu growth intenational cardiac vascular vascular rhythm heart rhythm heart structur heart structur heart peripher peripher invas therapi invas therapi gastrointestin gastrointestin therapi therapi growth growth intenational excl revenu growth revenu end revenu high end revenu pro-forma pro-forma y/yrevenu exhibit revenu model
exhibit price-to-earnings ntm past year base consensu estim
geographi worldwidegeographi internationalgeographi worldwiderevenu pro-forma revenu growth y/ycontribut revenu growth intenational cardiac vascular vascular rhythm heart rhythm heart structur heart structur heart peripher peripher invas therapi invas therapi gastrointestin gastrointestin therapi therapi growth growth intenational excl revenu growth revenu price-to-earnings ntm medic suppli devic
exhibit result versu estim
price target base ep estim y/i mdt
current price-to-earnings multipl ep estim target multipl key
assumpt underli ep estim revenu growth
basi point oper margin expans compani realiz
benefit enterpris excel program place excess free cash flow
dividend deploy primarili share buy-back price target basi
outperform rate
risk rate price target
lacklust growth key franchis includ pace defibril system atrial
fibril tavr drug-elut stent surgic innov brain pain therapi
inabl achiev target cost save manag believ achiev billion
gross save end enterpris excel program
project save fail materi ep estim could risk
risk price target rate includ potenti regulatori delay reject
failur devic clinic trial weaken demand key market price pressur
weak util trend fx
lead world-wide medic technolog compani engag manufactur
sell device-bas medic therapi compani oper four segment cardiac
vascular group restor therapi group diabet group minim invas
million except ep fy april
